​

Legend Biotech (LEGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LEGN Stock Forecast

Legend Biotech (LEGN) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $79.00, with a high of $83.00 and a low of $75.00. This represents a 136.10% increase from the last price of $33.46.

$30 $41 $52 $63 $74 $85 High: $83 Avg: $79 Low: $75 Last Closed Price: $33.46

LEGN Stock Rating

Legend Biotech stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (93.75%), 1 Hold (6.25%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 1 15 Strong Sell Sell Hold Buy Strong Buy

LEGN Price Target Upside V Benchmarks

TypeNameUpside
StockLegend Biotech136.10%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts-112
Avg Price Target-$75.00$82.83
Last Closing Price$33.46$33.46$33.46
Upside/Downside-124.15%147.55%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2510112--23
Mar, 2510112--23
Feb, 2510112--23
Jan, 2510112--23
Dec, 2410102--22
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 12, 2025Mitchell KapoorH.C. Wainwright$75.00$37.19101.67%124.15%
Nov 13, 2024Rick BienkowskiCantor Fitzgerald$83.00$55.9048.48%148.06%
Oct 15, 2024Justin ZelinBTIG$91.00$44.91102.63%171.97%
Oct 15, 2024Gena WangJohnson Rice$94.00$45.25107.73%180.93%
Oct 15, 2024Gena WangBarclays$94.00$44.91109.31%180.93%
Oct 08, 2024Qize DingRedburn Partners$86.00$49.5873.46%157.02%
Jun 17, 2024Edward TenthoffPiper Sandler$90.00$42.00114.29%168.98%
Jun 17, 2024Asthika GoonewardeneTruist Financial$88.00$42.45107.30%163.00%
May 23, 2024James ShinDeutsche Bank$60.00$40.0449.85%79.32%
May 17, 2024Matthew HarrisonMorgan Stanley$82.00$46.3776.84%145.07%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 12, 2025H.C. WainwrightBuyBuyhold
Dec 30, 2024Johnson RiceOverweightOverweighthold
Nov 13, 2024Cantor FitzgeraldOverweightOverweighthold
Oct 16, 2024BMO CapitalOutperformOutperformhold
Oct 16, 2024Johnson RiceBuyBuyhold
Oct 15, 2024BTIGBuyBuyhold
Oct 15, 2024Johnson RiceOverweightOverweighthold
Oct 15, 2024BarclaysOverweightOverweighthold
Oct 11, 2024Cowen & Co.BuyBuyhold
Oct 04, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.57$-2.74$-2.81$-2.94-----
Avg Forecast$-1.37$-1.56$-1.40$-1.41$-0.86$-0.41$0.55$1.18$1.87
High Forecast$-1.10$-1.25$-1.17$-1.37$-0.59$0.75$0.90$1.39$2.21
Low Forecast$-1.67$-1.90$-1.61$-1.46$-1.14$-1.18$0.19$0.94$1.49
Surprise %87.59%75.64%100.71%108.51%-----

Revenue Forecast

$0 $600M $1B $2B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$75.68M$89.79M$117.00M$285.14M-----
Avg Forecast$51.63M$72.44M$131.97M$297.01M$619.16M$1.02B$1.52B$2.08B$2.58B
High Forecast$60.43M$84.78M$147.55M$308.48M$645.03M$1.18B$1.53B$2.11B$2.94B
Low Forecast$43.76M$61.40M$115.57M$285.13M$601.04M$853.64M$1.52B$2.06B$2.18B
Surprise %46.56%23.95%-11.34%-3.99%-----

Net Income Forecast

$-550M $-360M $-170M $20M $210M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-303.48M$-386.21M$-446.35M$-518.25M-----
Avg Forecast$-241.23M$-274.51M$-246.49M$-249.08M$-152.60M$-160.21M$140.26M$205.44M$328.97M
High Forecast$-193.43M$-220.11M$-206.67M$-241.41M$-104.04M$132.16M$158.41M$245.33M$389.30M
Low Forecast$-294.67M$-335.32M$-284.32M$-256.76M$-201.15M$-207.88M$34.05M$165.56M$262.73M
Surprise %25.80%40.69%81.08%108.06%-----

LEGN Forecast FAQ

Is Legend Biotech stock a buy?

Legend Biotech stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Legend Biotech is a favorable investment for most analysts.

What is Legend Biotech's price target?

Legend Biotech's price target, set by 16 Wall Street analysts, averages $79 over the next 12 months. The price target range spans from $75 at the low end to $83 at the high end, suggesting a potential 136.10% change from the previous closing price of $33.46.

How does Legend Biotech stock forecast compare to its benchmarks?

Legend Biotech's stock forecast shows a 136.10% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Legend Biotech over the past three months?

  • April 2025: 43.48% Strong Buy, 47.83% Buy, 8.70% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 43.48% Strong Buy, 47.83% Buy, 8.70% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 43.48% Strong Buy, 47.83% Buy, 8.70% Hold, 0% Sell, 0% Strong Sell.

What is Legend Biotech’s EPS forecast?

Legend Biotech's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.86, marking a -70.75% decrease from the reported $-2.94 in 2023. Estimates for the following years are $-0.41 in 2025, $0.55 in 2026, $1.18 in 2027, and $1.87 in 2028.

What is Legend Biotech’s revenue forecast?

Legend Biotech's average annual revenue forecast for its fiscal year ending in December 2024 is $619.16M, reflecting a 117.14% increase from the reported $285.14M in 2023. The forecast for 2025 is $1.02B, followed by $1.52B for 2026, $2.08B for 2027, and $2.58B for 2028.

What is Legend Biotech’s net income forecast?

Legend Biotech's net income forecast for the fiscal year ending in December 2024 stands at $-153M, representing a -70.56% decrease from the reported $-518M in 2023. Projections indicate $-160M in 2025, $140.26M in 2026, $205.44M in 2027, and $328.97M in 2028.